Eric Jonasch, MD

Eric Jonasch, MD, discusses preliminary findings from a trial investigating NKT-2152 in previously treated advanced clear cell renal cell carcinoma.

Eric Jonasch, MD, discusses the goals of a meeting sponsored by the International Kidney Cancer Coalition that will focus on patient advocacy in GU malignancies.

Eric Jonasch, MD, discusses the evolution of belzutifan in cancer care, highlighting the agent’s potential for the treatment of patients with renal cell carcinoma.

Eric Jonasch, MD, discusses the promise of the hypoxia inducible factor-2 alpha inhibitor belzutifan in metastatic renal cell carcinoma.

Shared insight on the evolving treatment landscape of renal cell carcinoma and expectations for future evolution in the paradigm.

Before closing out there review of non–clear cell RCC management, expert oncologists highlight novel therapeutic strategies and ongoing clinical trials.

Eric Jonasch, MD, discusses the exploration of cabozantinib in the neoadjuvant setting in renal cell carcinoma.

Moving on to discuss the management of non–clear cell renal cell carcinoma, panelists consider cornerstone treatment options in this setting.

Comprehensive insight to the optimal selection and sequencing of therapy for advanced clear cell RCC in the second-line setting and beyond.

Centering their discussion on the second-line setting, expert oncologists review mainstay second-line therapies for advanced clear cell RCC.

Expert perspectives on key clinical trials studying first-line adjuvant therapy in patients with advanced clear cell renal cell carcinoma.

Focusing on novel first-line triplet therapy combinations, panelists consider which regimens may find a role in the management of advanced clear cell RCC.

An expert panel reviews novel first-line doublet therapies being studied in patients with advanced clear cell renal cell carcinoma.

Before closing out their review of mainstay combination therapy in the first-line setting of advanced clear cell RCC, panelists reflect on available quality of life data.

Focused discussion on brain metastases or sarcomatoid disease in advanced clear cell RCC and the selection of first-line treatment regimens.

Shared insight on the importance of sites of metastases and how they may impact first-line treatment selection in advanced clear cell RCC.

Centering conversation on systemic therapy, panelists review trial data behind the first-line combination regimens for patients with advanced clear cell RCC.

Comprehensive insight to the role of nephrectomy over systemic therapy in patients who receive a diagnosis of advanced clear cell RCC.

Expert oncologists open their discussion on advanced clear cell RCC by identifying its prevalence and prognoses before moving into treatment considerations.

Eric Jonasch, MD, discusses the best patient population when treating with belzutifan in clear cell renal cell carcinoma.

Eric Jonasch, MD, discusses the future of belzutifan (Welireg) in clear cell renal cell carcinoma.

Eric Jonasch, MD, discusses the investigation of belzutifan (Welireg) in clear cell renal cell carcinoma.

Drs Sumeet Bhatia and Eric Jonasch highlight unmet needs in advanced renal cell carcinoma and share clinical pearls.

Dr Sumeet Bhatia highlights the challenges faced by community oncologists who treat patients with advanced renal cell carcinoma and which patients they refer to academic centers.

Two oncologists describe common adverse events seen with IO-IO combination treatment regimens for advanced renal cell carcinoma, and how they interpret quality of life data from the CheckMate 214 trial.

Experts discuss how to treat advanced renal cell carcinoma with brain metastases and when to refer patients to an academic center.

Treating a patient with advanced renal cell carcinoma with ipilimumab-nivolumab based on data from the CheckMate 214 trial.

Sumeet Bhatia, MD, presents the patient profile of a 47-year-old male patient with advanced renal cell carcinoma.

Two key opinion leaders review data from a phase 3 clinical trial assessing the use of lenvatinib plus pembrolizumab for the treatment of advanced renal cell carcinoma.

Two oncologists describe common adverse events seen with I/O–TKI combination treatment regimens for advanced renal cell carcinoma and when they choose to stop the therapy.